Yves Luder

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration

Kim Lauper, Dan Nordström, Karel Pavelká et al. · Annals of the Rheumatic Diseases · 2018 · 71 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial

Robert Spiera, Sebastian Unizony, Min Bao et al. · Seminars in Arthritis and Rheumatism · 2021 · 43 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13

Treatment failure in giant cell arteritis

Sebastian Unizony, Min Bao, Jian Han et al. · Annals of the Rheumatic Diseases · 2021 · 43 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis

Kim Lauper, Denis Mongin, Florenzo Iannone et al. · Seminars in Arthritis and Rheumatism · 2019 · 25 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis

Andrea Rubbert‐Roth, Daniel Aletaha, Jenny Devenport et al. · Lara D. Veeken · 2020 · 18 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15